Surgery vs. watch-and-wait for liver cancer that responded to other treatments
Part of Cancer, Digestive system clinical trials.
This trial compares surgery against active monitoring for patients whose liver cancer shrank or disappeared after initial treatments. The goal is to determine which approach offers better outcomes for those who have had a good response to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 80 years old
- Liver cancer that is advanced, has spread, or cannot be surgically removed initially, and has responded well to previous drug or local therapy
- Good liver function (Child-Pugh class A) and enough healthy liver tissue remaining after potential surgery
- No severe heart, lung, or kidney disease, and no active bleeding or serious infections
- No other active cancers in the last 5 years (except minor skin or cervical cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying people with liver cancer (hepatocarcinoma) whose cancer returns (recurs) or never fully goes away (persists) after surgery. It looks at patterns after treatment at a specific study center, which may help guide better care for future patients.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
This trial tests a combination of liver-directed chemotherapy (HAIC), a targeted drug (lenvatinib), and an immunotherapy (envafolimab) to see if it can shrink liver cancers that are difficult to operate on. The goal is to make these cancers removable by surgery.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.